Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gliclazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gliclazide SCHEMBL16387 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL1537023 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL239075 | 0.99 | ALDH1A1 (0.97) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL6344915 | 0.94 | ALDH1A1 (0.88) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL30011556 | 0.93 | ALDH1A1 (0.86) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL6679802 | 0.90 | ALDH1A1 (0.80) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL1967443 | 0.88 | ALDH1A1 (0.77) | ALDH1A1LMNAAKR1C3GAATP53 | |
| SCHEMBL17309638 | 0.86 | ALDH1A1 (0.76) | ALDH1A1LMNAAKR1C3GAATP53 | |
| SCHEMBL17309632 | 0.85 | ALDH1A1 (0.74) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL22069924 | 0.85 | ALDH1A1 (0.72) | ALDH1A1LMNAAKR1C3GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2026 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127433-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2019-05-02 | — | — | US | claimed |
| US-10174093-B2 | Glucagon/GLP-1 receptor co-agonists | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-01-08 | — | — | US | claimed |
| WO-2018175537-A1 | SELECTIVE INHIBITION OF GLUCONEOGENIC ACTIVITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-09-27 | — | — | WO | claimed |
| US-20170349642-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2017-12-07 | — | — | US | claimed |
| US-9758562-B2 | Glucagon/GLP-1 receptor co-agonists | Indiana University and Technology Corporation (US) | 2017-09-12 | — | — | US | claimed |
| EP-2046341-B1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES AND NEUROPSYCHOLOGICAL DYSFUNCTION | Assistance Publique Hôpitaux De Paris (FR) | 2016-07-13 | — | — | EP | claimed |
| US-20160058881-A1 | PRODRUGS WITH PROLONGED ACTION | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2016-03-03 | — | — | US | claimed |
| EP-2986314-A2 | PRODRUGS WITH PROLONGED ACTION | Indiana University Research and Technology Corporation (US) | 2016-02-24 | — | — | EP | claimed |
| CN-105324125-A | Prodrugs with prolonged action | UNIV INDIANA RES & TECH CORP | 2016-02-10 | — | — | CN | claimed |
| WO-2014152460-A2 | PRODRUGS WITH PROLONGED ACTION | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-09-25 | — | — | WO | claimed |
| US-8729017-B2 | Glucagon/GLP-1 receptor co-agonists | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-05-20 | — | — | US | claimed |
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | claimed |
| EP-2487184-A1 | Glucagon/GLP-1 receptor co-agonists | Indiana University Research and Technology Corporation (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011123719-A2 | USE OF FAAH INHIBITORS FOR TREATING ABDOMINAL, VISCERAL AND PELVIC PAIN | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| EP-2046341-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES AND NEUROPSYCHOLOGICAL DYSFUNCTION | Assistance Publique - Hopitaux de Paris (FR) | 2009-04-15 | — | — | EP | claimed |
| CN-101138568-A | Application of hydrochloric acid in the preparation of medicament for treating diabetes and prostate gland disease | ZHIREN LIU (CN) | 2008-03-12 | — | — | CN | claimed |
| WO-2008015226-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES AND NEUROPSYCHOLOGICAL DYSFUNCTION | ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) | 2008-02-07 | — | — | WO | claimed |
| EP-1884244-A1 | Potassium channel ligands for treating diabetes and neuropsychological dysfunction | Assistance Publique - Hopitaux de Paris (FR) | 2008-02-06 | — | — | EP | claimed |
| WO-2006034435-A2 | METHODS AND COMPOSITIONS FOR TREATING GLUCOSE-ASSOCIATED CONDITIONS, METABOLIC SYNDROME, DYSLIPIDEMIAS AND OTHER CONDITIONS | POINT THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| CN-1524543-A | Medicament formulation for preventing and treating diabetes complication and preparation method therefor | 天津市长生基因生物工程有限公司 | 2004-09-01 | — | — | CN | claimed |